Comparative bioavailability of enrofloxacin in dogs when concealed in noncommercial morsels, either as tablet or as enrofloxacin–alginate dried beads
- 28 October 2020
- journal article
- research article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 44 (4) , 522-532
Abstract
Administration of enrofloxacin tablets concealed in improvised morsels to elude the unpleasant flavor of this drug is likely to diminish maximum plasma concentrations (Cmax) reached by this drug, jeopardizing treatment efficacy. To avoid this, the hypothesis that alginate dried beads containing enrofloxacin (ADBE) could modify the pharmacokinetics of enrofloxacin in dogs was tested. ADBE were manufactured and pharmaceutically defined as having high entrapment efficiency (>90%) and a drug loading capacity of 56%–67%. Based on the hydrophilic nature of alginate and its interaction with the anionic charge of the amino groups of enrofloxacin, a novel modified release system was obtained in which ADBE give place to both a rapid diffusion releasing of enrofloxacin and a maintained release. The ADBE concealed in a sausage (ADBEs) achieved both the highest Cmax (5.1 µg/ml ± 0.3 SD) and the area under the concentration versus time (AUC0–24) (41.2 µg hr−1 ml−1 ± 6.9 SD). The tablet administered alone had a Cmax of 1.9 µg/ml ± 0.3 SD and an AUC0–24 = 16.5 µg h−1 ml−1 ± 3.5 SD, while the tablet concealed in a sausage reached a Cmax of 1.2 µg/ml ± 0.3 SD with an AUC0–24 = 12.3 µg hr−1 ml−1 ± 3.8 SD (p < .05 in both cases when confronting ADBEs vs. tablets). Consequently, Cmax/MIC and AUC0–24/MIC ratios are higher for ADBEs. Other PK parameters were statistically indistinguishable, and other morsels containing enrofloxacin as a tablet or as ADBE rendered less favorable PK parameters. Due to ease of administration and favorable PK for ADBE concealed in a sausage, this pharmaceutical design can be regarded as PK/PD consistent and worthy of clinical studies.Keywords
This publication has 22 references indexed in Scilit:
- Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suisPLOS ONE, 2019
- Food intake attenuates the drug interaction between new quinolones and aluminumJournal of Pharmaceutical Health Care and Sciences, 2018
- Characterization of alginate beads with encapsulated cocoa extract to prepare functional food: Comparison of two gelation mechanismsFood Hydrocolloids, 2015
- Formulation of enrofloxacin SLNs and its pharmacokinetics in emu (Dromaius novaehollandiae) birdsApplied Nanoscience, 2014
- Physicochemical characterization and pharmacokinetics in broiler chickens of a new recrystallized enrofloxacin hydrochloride dihydrateJournal of Veterinary Pharmacology and Therapeutics, 2014
- Polyvinylpyrrolidone oral films of enrofloxacin: Film characterization and drug releaseInternational Journal of Pharmaceutics, 2014
- Food Drug InteractionsOman Medical Journal, 2011
- Pharmacology of the fluoroquinolones: A perspective for the use in domestic animalsThe Veterinary Journal, 2006
- Simple, rapid determination of enrofloxacin and ciprofloxacin in bovine milk and plasma by high-performance liquid chromatography with fluorescence detectionJournal of Pharmaceutical and Biomedical Analysis, 2004
- A Comprehensive Model for Enrofloxacin to Ciprofloxacin Transformation and Disposition in DogJournal of Pharmaceutical Sciences, 1997